头雁
头雁|11月 21, 2026 08:29
Steve Jobs died of pancreatic cancer, a disease previously notoriously difficult to cure. It seems there's new progress. The company developing this drug to control pancreatic cancer growth is Revolution Medicines (NASDAQ: RVMD), with a market capitalization of approximately $34 billion. This is the first targeted therapy approved for pancreatic cancer. It has also been approved in Europe. The company's published treatment data: Revolution Medicines presented first-line combination therapy data from its Phase 1/2 trial at the symposium (ENA 2026): In 61 patients with metastatic pancreatic cancer treated as first-line therapy: - Disease control rate (DCR): 90.2% – Tumor shrinkage or cessation of growth. - Objective response rate (ORR): 60.7% – Actual tumor shrinkage, with 8.2% achieving complete response (tumor disappearance on imaging). - Median progression-free survival (PFS): 12.8 months. - 12-month overall survival: Approximately 76.6%.
Share To

HotFlash

APP

X

Telegram

Facebook

Reddit

CopyLink

Hot Reads